NanoRepro AG Net Assets
NanoRepro AG net assets. Based on the latest financial reports, NanoRepro AG (NN6) has net assets worth €36.15 Million EUR (≈ $42.27 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€36.83 Million ≈ $43.06 Million USD) and total liabilities (€678.46K ≈ $793.19K USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore NanoRepro AG net asset momentum to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €36.15 Million |
| % of Total Assets | 98.16% |
| Annual Growth Rate | 34.37% |
| 5-Year Change | -37.24% |
| 10-Year Change | 1091.39% |
| Growth Volatility | 207.17 |
Net Assets of NanoRepro AG (2008–2025)
Net assets of NanoRepro AG from 2008 to 2025. This chart illustrates how NanoRepro AG's net assets have evolved over time, based on quarterly financial data. See NanoRepro AG (NN6) net asset quality to measure how much of total assets are equity-financed.
Annual Net Assets for NanoRepro AG (2008–2025)
The table below shows the annual net assets of NanoRepro AG from 2008 to 2025. For live market cap and overall valuation, see NanoRepro AG (NN6) total market value.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €36.15 Million ≈ $42.27 Million |
-5.21% |
| 2024-12-31 | €38.14 Million ≈ $44.59 Million |
-5.53% |
| 2023-12-31 | €40.38 Million ≈ $47.20 Million |
-14.88% |
| 2022-12-31 | €47.43 Million ≈ $55.45 Million |
-17.66% |
| 2021-12-31 | €57.61 Million ≈ $67.35 Million |
+621.00% |
| 2020-12-31 | €7.99 Million ≈ $9.34 Million |
+80.40% |
| 2019-12-31 | €4.43 Million ≈ $5.18 Million |
-21.16% |
| 2018-12-31 | €5.62 Million ≈ $6.57 Million |
+46.91% |
| 2017-12-31 | €3.82 Million ≈ $4.47 Million |
+26.01% |
| 2016-12-31 | €3.03 Million ≈ $3.55 Million |
+33.44% |
| 2015-12-31 | €2.27 Million ≈ $2.66 Million |
+19.25% |
| 2014-12-31 | €1.91 Million ≈ $2.23 Million |
+15.96% |
| 2013-12-31 | €1.64 Million ≈ $1.92 Million |
+90.74% |
| 2012-12-31 | €862.16K ≈ $1.01 Million |
+0.47% |
| 2011-12-31 | €858.14K ≈ $1.00 Million |
-45.30% |
| 2010-12-31 | €1.57 Million ≈ $1.83 Million |
+671.10% |
| 2009-12-31 | €203.45K ≈ $237.85K |
-14.62% |
| 2008-12-31 | €238.29K ≈ $278.58K |
-- |
Equity Component Analysis
This analysis shows how different components contribute to NanoRepro AG's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 231598038.0% over the analyzed period, indicating profitable operations and earnings retention.
NanoRepro AG Net Assets Breakdown (December 2025)
NanoRepro AG net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €1.09 Million | 3.03% |
| Common Stock | €12.90 Million | 35.69% |
| Other Comprehensive Income | €22.45 Million | 62.08% |
| Total Equity | €36.15 Million | 100.00% |
NanoRepro AG Competitors by Market Cap
The table below lists competitors of NanoRepro AG ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Mepet Metro Petrol ve Tesisleri Sanayi Ticaret AS
IS:MEPET
|
$22.46 Million |
|
Prestige Wealth Inc.
NASDAQ:AURE
|
$22.46 Million |
|
Diversified Gateway Solutions Bhd
KLSE:0131
|
$22.47 Million |
|
Key Tronic Corporation
NASDAQ:KTCC
|
$22.48 Million |
|
LITHIUMBANK RESOURCES
F:HT9
|
$22.42 Million |
|
Plutus Financial Group Limited Ordinary Shares
NASDAQ:PLUT
|
$22.41 Million |
|
Rackla Metals Inc
V:RAK
|
$22.40 Million |
|
M4B SA ZY 8
F:24D
|
$22.38 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in NanoRepro AG's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 38,141,276 to 36,154,163, a change of -1,987,113 (-5.2%).
- Net loss of 1,987,112 reduced equity.
- Other comprehensive income increased equity by 22,446,205.
- Other factors decreased equity by 22,446,206.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-1.99 Million | -5.5% |
| Other Comprehensive Income | €22.45 Million | +62.08% |
| Other Changes | €-22.45 Million | -62.08% |
| Total Change | €- | -5.21% |
Book Value vs Market Value Analysis
This analysis compares NanoRepro AG's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.55x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 7.54x to 0.55x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2008-12-31 | €0.21 | €1.57 | x |
| 2009-12-31 | €0.18 | €1.57 | x |
| 2010-12-31 | €1.37 | €1.57 | x |
| 2011-12-31 | €0.75 | €1.57 | x |
| 2012-12-31 | €0.75 | €1.57 | x |
| 2013-12-31 | €0.19 | €1.57 | x |
| 2014-12-31 | €0.22 | €1.57 | x |
| 2015-12-31 | €0.52 | €1.57 | x |
| 2016-12-31 | €0.54 | €1.57 | x |
| 2017-12-31 | €0.56 | €1.57 | x |
| 2018-12-31 | €0.66 | €1.57 | x |
| 2019-12-31 | €0.51 | €1.57 | x |
| 2020-12-31 | €0.86 | €1.57 | x |
| 2021-12-31 | €4.46 | €1.57 | x |
| 2022-12-31 | €3.68 | €1.57 | x |
| 2023-12-31 | €3.18 | €1.57 | x |
| 2024-12-31 | €3.02 | €1.57 | x |
| 2025-12-31 | €2.87 | €1.57 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently NanoRepro AG utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -5.50%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -42.70%
- • Asset Turnover: 0.13x
- • Equity Multiplier: 1.02x
- Recent ROE (-5.50%) is above the historical average (-54.25%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2008 | -330.81% | -1170.94% | 0.16x | 1.82x | €-812.12K |
| 2009 | -216.68% | -194.37% | 0.50x | 2.21x | €-461.17K |
| 2010 | -41.31% | -206.49% | 0.16x | 1.24x | €-804.93K |
| 2011 | -209.10% | -215.79% | 0.83x | 1.16x | €-1.88 Million |
| 2012 | -68.37% | -63.05% | 0.88x | 1.23x | €-675.70K |
| 2013 | -30.27% | -47.78% | 0.58x | 1.09x | €-662.14K |
| 2014 | -1.42% | -2.58% | 0.48x | 1.14x | €-217.70K |
| 2015 | -51.70% | -193.50% | 0.25x | 1.07x | €-1.40 Million |
| 2016 | -18.18% | -29.78% | 0.53x | 1.16x | €-855.14K |
| 2017 | -19.20% | -37.23% | 0.47x | 1.10x | €-1.12 Million |
| 2018 | -5.16% | -10.54% | 0.47x | 1.03x | €-851.39K |
| 2019 | -26.84% | -97.56% | 0.25x | 1.08x | €-1.63 Million |
| 2020 | 21.21% | 10.01% | 1.52x | 1.40x | €895.92K |
| 2021 | 51.59% | 18.27% | 2.06x | 1.37x | €23.96 Million |
| 2022 | -7.85% | -9.68% | 0.78x | 1.04x | €-8.47 Million |
| 2023 | -11.60% | -147.17% | 0.08x | 1.03x | €-8.72 Million |
| 2024 | -5.36% | -44.02% | 0.12x | 1.02x | €-5.86 Million |
| 2025 | -5.50% | -42.70% | 0.13x | 1.02x | €-5.60 Million |
Industry Comparison
This section compares NanoRepro AG's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $3,433,311,525
- Average return on equity (ROE) among peers: -40.32%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| NanoRepro AG (NN6) | €36.15 Million | -330.81% | 0.02x | $22.45 Million |
| IZOTROPIC CORP. (1R3) | $-3.85 Million | 0.00% | 0.00x | $6.11 Million |
| ALPHAHELIX MOL.DIAGN. SK1 (4MB) | $4.18 Million | -188.49% | 2.68x | $839.64K |
| HANGZHOU TIGERMED CO. H 1 (5HZ1) | $24.45 Billion | 8.28% | 0.21x | $604.57 Million |
| Check-Cap Ltd (7CC) | $16.38 Million | -84.54% | 0.20x | $9.20 Million |
| INTERGRATED DIA.H DL 025 (8I8) | $3.50 Billion | 30.79% | 1.04x | $251.46 Million |
| GENETIC ANALYSIS NK -60 (8V8) | $32.00 Million | -74.44% | 0.67x | $2.36 Million |
| GENINCODE PLC LS -01 (9PL) | $7.90 Million | -70.37% | 0.49x | $5.28 Million |
| INOVIQ LTD. (EGQ0) | $28.29 Million | -64.31% | 0.09x | $13.50 Million |
| Eurofins Scientific SE (ESF0) | $4.68 Billion | 16.73% | 1.00x | $11.18 Billion |
| ICON Public Limited Company (IJF) | $1.62 Billion | 23.11% | 0.80x | $7.52 Billion |
About NanoRepro AG
NanoRepro AG engages in the development, manufacture, and distribution of rapid diagnostic tests and food supplements for home and professional use in Germany and internationally. The company provides products in the areas of family planning and disease detection, as well as food intolerances, allergies, and infectious diseases. It offers rapid diagnostic tests, such as family planning, and preve… Read more